Liberate Bio
Liberate Bio develops non-viral delivery technologies for nucleic acid cargoes, aiming to address genetic disorders.
About Liberate Bio
Liberate Bio focuses on advancing non-viral delivery technologies for nucleic acid cargoes such as ASOs and siRNAs. The company aims to develop new vehicles to deliver oligonucleotide cargos, addressing genetic disorders. With a team of 50 employees, Liberate Bio operates within the biotechnology industry, working on innovative solutions for targeted delivery systems.
Company Facts
- Headquarters
- Boston
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- seed
- Total Funding
- $31,000,000
- Last Funding Type
- seed
- Last Funding Date
- 2025-10-15
- Website
- liberatebio.com
Industries & Categories
Bioinformatics, Biotechnology, Genetics
Social Links
Canonical: https://fsome.com/organization/liberate-bio-25606 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.